Endocrine Today has compiled a list of the top recent news reports related to testosterone therapy. In March, readers were interested in essential oils disrupting endocrine function, semaglutide producing weight loss and the safety of an artificial pancreas.Testosterone decanoate powder
Three new testosterone therapies offer innovative drug delivery options for men with hypogonadism that improve patient satisfaction while avoiding risks related to secondary exposure.
Long-term testosterone therapy may not only help men with obesity and hypogonadism to lose weight, but it may have other useful effects on metabolic function and protect against obesity comorbidities.
Premenopausal and postmenopausal women reporting a persistent, low libido that profoundly impairs quality of life can experience an improvement in symptoms with transdermal testosterone, but clinicians must consider several important points before prescribing the therapy.
The FDA approved testosterone undecanoate in an oral capsule to treat men with certain forms of hypogonadism, the agency announced in a press release. The approval of Jatenzo (Clarus Therapeutics) marks the first new oral testosterone replacement product in more than 60 years.
Men with obesity and hypogonadism who underwent testosterone therapy achieved greater 10-year weight loss and experienced protective effects against cardiovascular and mortality risks compared with similar men who did not receive testosterone.Low-dose human chorionic gonadotropin, or hCG, may preserve spermatogenesis in men with hypogonadism treated with intramuscular or transdermal testosterone replacement therapy.